共 33 条
[1]
ALBAIN K, 2004, BREAST CANC RES TREA, V88
[3]
Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance
[J].
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE,
2005, 97 (17)
:1254-1261
[5]
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
[J].
JOURNAL OF CLINICAL ONCOLOGY,
2005, 23 (16)
:3676-3685
[6]
Chang J, 2000, CANCER-AM CANCER SOC, V89, P2145, DOI 10.1002/1097-0142(20001201)89:11<2145::AID-CNCR1>3.3.CO
[7]
2-J
[9]
Cancer risk prediction models: A workshop on development, evaluation, and application
[J].
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE,
2005, 97 (10)
:715-723
[10]
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
[J].
LANCET,
2010, 375 (9712)
:377-384